Association of metabolic syndrome to the development of diabetes mellitus 2. Type and atherosclerosis;Vzt'ah metabolického syndrómu k rozvoju diabetes mellitus 2. Typu a aterosklerózy

Kardiologia

Volumn 14, Issue 3, 2005, Pages 133-137

  Tkáč, Ivan ^a  

^a Urologické oddelenie FN L Pasteura   (Slovakia)

Author keywords

Metabolic syndrome; Prevention of atherosclerosis; Prevention of diabetes mellitus; Risk factors of atherosclerosis

Indexed keywords

ACARBOSE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; METFORMIN; RAMIPRIL; TROGLITAZONE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPED COUNTRY; DIET THERAPY; DISEASE ASSOCIATION; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEALTH STATUS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; KINESIOTHERAPY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

EID: 18144362507     PISSN: 12100048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;287:356-359.
3. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002;25:1129-1134.
4. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
5. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 and older. Diabetes 2003;52:1210-1214.
6. Chalasani N, Deeg MA, Persohn S, et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:1849-1855.
7. Stavenow L, Kjelström T. Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 middle aged males: interaction with serum cholesterol. Atherosclerosis 1999;147:243-247.
8. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75.
9. Tkáč I, Kimball BP, Lewis G, et al. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 1997;17:3633-3638.
10. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995;92:1779-1985.
11. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162:2597-2604.
12. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-27.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016.
14. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre placebo-controlled trial. Lancet 2004;364:685-696.
15. Gerstein HC, Mann JFE, Yi QL, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001;286:421-426.
16. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. J Am Med Assoc 2001;286:1881-1885.
17. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study. J Hypertension 2002;20:1879-1886.
18. Charles MA, Morange P, Eschwege E, et al. on behalf of the BIGPRO Study Group. Effect of weight change and metformin on fibrinolysis and the von Willebrand Factor in obese nondiabetic subjects. Diabetes Care 1998;21:1967-1972.
19. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-397.
20. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
21. Melenovsky V, Malik J, Wichterle D, et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002;144:E6.
22. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:S5-S20.
23. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544.
24. Tuomilehto J, Lindström, J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by change in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
25. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
26. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077.
27. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. J Am Med Assoc 2003;290:486-494.
28. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803.